Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alain H Rook

Showing results (61-70 of 98) with videos related to

Pageof 10
Sort By:
Journal of the American Academy of Dermatology|April 26, 2006
A randomized, double-blind, placebo-controlled trial of photopheresis in systemic sclerosisRobert M Knobler, Lars E French, Youn Kim, et al.
Archives of Dermatology|August 8, 2002
Treatment of cutaneous T-cell lymphoma with combined immunomodulatory therapy: a 14-year experience at a single institutionKaren Rebecca Suchin, Andrew J Cucchiara, Scott L Gottleib, et al.
American Journal of Hematology|February 28, 2012
The histone deacetylase inhibitor, romidepsin, suppresses cellular immune functions of cutaneous T-cell lymphoma patientsMichael J Kelly-Sell, Youn H Kim, Suzanne Straus, et al.
Leukemia & Lymphoma|March 21, 2015
Clinically significant responses achieved with romidepsin across disease compartments in patients with cutaneous T-cell lymphomaEllen J Kim, Youn H Kim, Alain H Rook, et al.
American Journal of Hematology|June 5, 2007
Bexarotene blunts malignant T-cell chemotaxis in Sezary syndrome: reduction of chemokine receptor 4-positive lymphocytes and decreased chemotaxis to thymus and activation-regulated chemokineStephen K Richardson, Sarah B Newton, Tami L Bach, et al.
The Journal of Investigative Dermatology|June 25, 2013
CD164 and FCRL3 are highly expressed on CD4+CD26- T cells in Sézary syndrome patientsMaria Wysocka, Andrew V Kossenkov, Bernice M Benoit, et al.
Cancers|July 29, 2025
Cutaneous T-Cell Lymphoma: Yin-Yang Effects of Transcription Factors HLF and NFIL3 in Regulation of Malignant T-Cell Markers in the Context of HDAC Inhibitor Romidepsin TreatmentAndrew V Kossenkov, Noor Dawany, Sonali Majumdar, et al.
The Journal of Clinical Investigation|April 21, 2005
Immunopathogenesis and therapy of cutaneous T cell lymphomaEllen J Kim, Stephen Hess, Stephen K Richardson, et al.
Blood|June 19, 2008
Clinical and in vitro resistance to bexarotene in adult T-cell leukemia: loss of RXR-alpha receptorJulie H Lin, Ellen J Kim, Anand Bansal, et al.
The Journal of Experimental Medicine|June 5, 2003
Classification and prediction of survival in patients with the leukemic phase of cutaneous T cell lymphomaLaszlo Kari, Andrey Loboda, Michael Nebozhyn, et al.
Pageof 10

Showing results (61-70 of 98) with videos related to

Sort By:
Pageof 10
Journal of the American Academy of Dermatology|April 26, 2006
A randomized, double-blind, placebo-controlled trial of photopheresis in systemic sclerosisRobert M Knobler, Lars E French, Youn Kim, et al.
Archives of Dermatology|August 8, 2002
Treatment of cutaneous T-cell lymphoma with combined immunomodulatory therapy: a 14-year experience at a single institutionKaren Rebecca Suchin, Andrew J Cucchiara, Scott L Gottleib, et al.
American Journal of Hematology|February 28, 2012
The histone deacetylase inhibitor, romidepsin, suppresses cellular immune functions of cutaneous T-cell lymphoma patientsMichael J Kelly-Sell, Youn H Kim, Suzanne Straus, et al.
Leukemia & Lymphoma|March 21, 2015
Clinically significant responses achieved with romidepsin across disease compartments in patients with cutaneous T-cell lymphomaEllen J Kim, Youn H Kim, Alain H Rook, et al.
American Journal of Hematology|June 5, 2007
Bexarotene blunts malignant T-cell chemotaxis in Sezary syndrome: reduction of chemokine receptor 4-positive lymphocytes and decreased chemotaxis to thymus and activation-regulated chemokineStephen K Richardson, Sarah B Newton, Tami L Bach, et al.
The Journal of Investigative Dermatology|June 25, 2013
CD164 and FCRL3 are highly expressed on CD4+CD26- T cells in Sézary syndrome patientsMaria Wysocka, Andrew V Kossenkov, Bernice M Benoit, et al.
Cancers|July 29, 2025
Cutaneous T-Cell Lymphoma: Yin-Yang Effects of Transcription Factors HLF and NFIL3 in Regulation of Malignant T-Cell Markers in the Context of HDAC Inhibitor Romidepsin TreatmentAndrew V Kossenkov, Noor Dawany, Sonali Majumdar, et al.
The Journal of Clinical Investigation|April 21, 2005
Immunopathogenesis and therapy of cutaneous T cell lymphomaEllen J Kim, Stephen Hess, Stephen K Richardson, et al.
Blood|June 19, 2008
Clinical and in vitro resistance to bexarotene in adult T-cell leukemia: loss of RXR-alpha receptorJulie H Lin, Ellen J Kim, Anand Bansal, et al.
The Journal of Experimental Medicine|June 5, 2003
Classification and prediction of survival in patients with the leukemic phase of cutaneous T cell lymphomaLaszlo Kari, Andrey Loboda, Michael Nebozhyn, et al.
Pageof 10